NCT05326906View on ClinicalTrials.gov

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

May 1, 2021

Study Completion Date

May 1, 2022

Conditions
Lung Cancer
Interventions
DRUG

PD-1/PD-L1 inhibitors

PD-1/PD-L1 inhibitors (the dosage calculation according to dosing instructions)

Trial Locations (1)

Unknown

Hunan Cancer hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT05326906 - The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis | Biotech Hunter | Biotech Hunter